Promising studies suggest that APC could be coupled with the only currently approved treatment, tissue plasminogen activator (tPA), to protect the brain from tPA's very harmful side effects, in addition to preventing cell death from lack of oxygen (hypoxia).
Fixéronse prometedores estudos que indican que a APC podería ser acoplada xunto co único tratamento actualmente aprobado, o activador do plasminóxeno tisular (tPA), para protexer o cerebro dos efectos colaterais moi nocivos do tPA, ademais de impedir a morte celular por carencia de oxíxeno (hipoxia).